After-tax losses at Feedback, the specialist medical imaging technology company, rose to £266,003 in the year to the end of May from £183,156 last time.
Losses before interest, tax and amortisation widened to £252,750 from £206,523.
Revenues of £465,885 were up from £431,454 a year ago.
Chairman Dr Alastair Riddell said: 'We delivered solid operational progress during the period and the increased international sales exposure is particularly encouraging.
'Our technical and regulatory team have been working diligently on the delivery of a CE marked release of TexRAD Lung.
'We are acutely aware that this development has taken longer than originally expected, however we are confident that our rigorous regulatory review will pave the way for new products and therefore maximise the potential for TexRAD's clinical use worldwide.
'We remain focused on applying our leading research expertise to the clinical setting to drive future revenue growth.'
At 9:06am: (LON:FDBK) Feedback PLC share price was +0.15p at 2.18p